Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Androgen receptor monoclonal antibody (SPM335)

ENZ-ABS770-0100 100 µg 630.00 USD
Do you need bulk/larger quantities?

Product Details

Alternative Name:Dihydrotestosterone receptor, Nuclear receptor subfamily 3 group C member 4
Immunogen:Human androgen receptor, amino acids 302-318 (STEDTAEYSPFKGGYTK).
UniProt ID:P10275
Species reactivity:Human
Specificity:Recognizes a protein of 110kDa, which is identified as androgen receptor (AR). It reacts with full length, and the newly described A form of the receptor.
Crossreactivity:Does not cross react with estrogen, progesterone, or glucocorticoid receptors.
Application Notes:This mAb is superb for staining of formalin/paraffin tissues.
Purity Detail:Protein G affinity purified.
Formulation:Liquid. In 1X PBS containing 0.1 mg/ml BSA and 0.05% sodium azide.
Handling:Avoid freeze/thaw cycles.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C
Scientific Background:The expression of AR is reportedly inversely correlated with histologic grade i.e. well differentiated prostate tumors show higher expression than the poorly differentiated tumors. In prostate cancer, AR has been proposed, as a marker of hormone-responsiveness and thus it may be useful in identifying patients likely to benefit from anti-androgen therapy. Anti-androgen receptor has been useful clinically in differentiating morpheaform basal cell carcinoma (mBCC) from desmoplastic trichoepithelioma (DTE) in the skin.
Regulatory Status:RUO - Research Use Only
Androgen receptor monoclonal antibody (SPM335) IHC
IHC: Formalin-fixed, paraffin-embedded human prostate carcinoma stained with anti-Androgen Receptor antibody
Please mouse over
Androgen receptor monoclonal antibody (SPM335) IHC

Product Toolbox


Certificate of Analysis


By target:
Androgen receptor
By biological activity:
Androgen receptor Monoclonal antibody
By catalog section:


Technical Service
Customer Service
Keep in touch

©2022 Enzo Life Sciences, Inc.,